Cognition Therapeutics, Inc. announced positive results from its Phase 2 trials of zervimesine (CT1812) in treating dementia with Lewy bodies (DLB) and Alzheimer’s disease, indicating significant ...
Hosted on MSN
Researchers reveal potential molecular link between air pollutants and increased risk of Lewy body dementia
A team of researchers at Johns Hopkins Medicine say they have revealed a possible molecular connection between air pollution and an increased risk of developing Lewy body dementia. Subscribe to our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results